IPCALAB IPCA Laboratories Q3 FY26 results (Oct–Dec 2025) and concall
Ipca Labs reported a robust Q3 FY26 with consolidated revenue growth of 6.5% and significant EBITDA margin expansion, driven by strong domestic and export formulation performance. While the API business remained flat and Unichem faced challenges in its US portfolio, management outlined strategies for market share regain and margin improvement, including new product launches and capacity utilization. The company maintains a healthy cash position and is focusing on biosimilar development and green energy initiatives.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 6.5%, net profit up 31.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 +9% | 2,392 +7% |
| EBITDA | 441 | 463 | 429 | 416 | 545 +24% | 533 +15% |
| Net profit | 246 | 276 | 64 | 233 | 281 +14% | 364 +32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
